Q: Can you share with us your motivation and interest in antimicrobial resistance and development of rapid diagnostic methods for infectious disease? And why is this so important? A: We are fast approaching a time when antibiotics will no longer work and simple infections may become...
Q: Invitae wants to be the Amazon of genetic testing. What does that exactly mean and what does Invitae do that is different from other companies to achieve this? A: Invitae is proactively driving down the cost of genetic testing in order to make it more...
Q: What attracted you to join Genomic Health and what is your role? A:Genomic Health shifted the paradigm in cancer management, helping over 700,000 patients optimize their treatment decisions, and pioneering a new business model that has been followed by many companies in the last decade....
A: I was attracted to Inivata to help progress a technology I see can make a major impact in improving how we diagnose and manage patients with cancer. The field of liquid biopsy, and ctDNA analysis specifically, is undergoing rapid development and we’re only now...
Q: What were the motivations to create the Oncology Precision Network (OPeN)? A: As we began implementing precision oncology at our hospitals and clinics throughout Intermountain Healthcare, we quickly began to realize that there are certain variants or mutations in a patient’s tumor that we may...
Does Immunotherapy Measure Up to the Hype? Brigitte Ganter, PhD Disclosures | October 27, 2016 Editor’s Note: The emergence of immunotherapy has redefined cancer medicine. Among those who continue to redefine this expanding arena of clinical research, James P. Allison, PhD, of MD Anderson Cancer Center, holds a special place....
